A senior health official in Indonesia said the country is taking steps toward approving emergency usage of COVID-19 vaccine candidates from China, reported The Wall Street Journal.
Indonesia's government says it will procure 18 million doses by the end of the year from Sinovac Biotech, Sinopharm and CanSino Biologics, whose vaccines are still undergoing clinical trials in various parts of the world.
Healthcare workers, police and soldiers will be among the first to receive the vaccines under the emergency-use authorization, which could come as early as November, said Achmad Yurianto, director general of disease prevention and control at Indonesia's health ministry.
Indonesia is hosting a Phase III trial for the vaccine developed by Sinovac. The process, which began in August, hasn't revealed serious negative side effects for participants so far, Yurianto said.
The trial is scheduled to be completed over the next few months, potentially after emergency use begins in Indonesia.
To read more NewsPoints articles, click here.